CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 89 enrolled
Drug / intervention
Ibuprofen +1 moredrug
Likely dose
Ibuprofen 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01171794
NCT01171794Phase 3Completed
CompareCT.gov

Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)

Stanford University·interventional·Posted Jul 28, 2010·Updated Dec 13, 2018

In Brief

A Phase 3 clinical trial evaluating Ibuprofen and Placebo for Altitude Sickness. Completed, enrolled 89 participants across 1 site.

Detailed Summary

This is a research study on Altitude Illness. From the information collected and studied in this project we hope to learn more about Altitude Illness, including factors that may affect and prevent the development and progression of this condition. We hope to learn if the commonly used non-steroidal anti-inflammatory medication, ibuprofen can prevent altitude illness. Possible participants in this study are healthy adults who indicated they would like to participate, learn about altitude illness, and desire to hike Barcroft Peak. Stanford University researchers hope to enroll about 100 participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAltitude Sickness
CountriesUnited States
CollaboratorsUniversity of California, San Diego

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 28, 2010
Enrollment StartJul 1, 2010
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.9 years ago

Interventions

Ibuprofendrug

3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)

Placebodrug

identical number of visually identical tasteless pills as ibuprofen arm